Dachuang CaoFollowEli Lilly (United States)1 paperORCID 0000-0003-2291-9037OpenAlexPapersObesity PillarsHuman trial·2 hEvaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetesGLP-1 receptor agonists
Obesity PillarsHuman trial·2 hEvaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetesGLP-1 receptor agonists